Atlas Trials

Almirall, S.A.

65 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Almirall, S.A.

RecordFirmDate
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa (NCT07547813)Almirall, S.A.2026-05-13
A Study of Lebrikizumab in Adults With Nummular Eczema (NCT07542483)Almirall, S.A.2026-04-24
A Study of LAD106 in Healthy Adult Participants (NCT07471932)Almirall, S.A.2026-02-17
A Study of LAD603 in Adults With Alopecia Areata (NCT07311564)Almirall, S.A.2025-12-17
A Study of LAD191 in Adults With Hidradenitis Suppurativa (NCT07151937)Almirall, S.A.2025-11-05
A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis (NCT06815380)Almirall, S.A.2025-01-23
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (NCT06526182)Almirall, S.A.2024-07-03
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting (NCT06488170)Almirall, S.A.2024-04-04
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis (NCT06135415)Almirall, S.A.2023-12-21
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects (NCT06200597)Almirall, S.A.2023-12-05
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (NCT05990725)Almirall, S.A.2023-11-20
A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO) (NCT06029257)Almirall, S.A.2023-11-14
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis (NCT06030076)Almirall, S.A.2023-09-06
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults (NCT05811234)Almirall, S.A.2023-06-13
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis (NCT05916365)Almirall, S.A.2023-05-23
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses (NCT05741294)Almirall, S.A.2023-01-20
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp (NCT05387525)Almirall, S.A.2022-10-24
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease (NCT06488209)Almirall, S.A.2022-07-29
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis (NCT05279131)Almirall, S.A.2022-06-28
UV Sensor in Patients With Actinic Keratosis (NCT05481073)Almirall, S.A.2022-06-13
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis (NCT05260073)Almirall, S.A.2022-03-09
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine (NCT05149313)Almirall, S.A.2021-12-23
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study (NCT04823247)Almirall, S.A.2021-11-22
Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI) (NCT04322669)Almirall, S.A.2021-08-04
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES) (NCT04820673)Almirall, S.A.2021-03-09
Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis (NCT04339595)Almirall, S.A.2020-01-29
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) (NCT04229836)Almirall, S.A.2019-12-17
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice (NCT04203693)Almirall, S.A.2019-10-30
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (NCT04263610)Almirall, S.A.2019-09-04
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (NCT03285477)Almirall, S.A.2017-09-18
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) (NCT03285490)Almirall, S.A.2017-09-15

Track Almirall, S.A. automatically

Every clearance here is in the API, with alerts when new ones post.